10-K/APeriod: FY2012

ABBOTT LABORATORIES Annual Report (Amendment), Year Ended Dec 31, 2012

Filed March 27, 2013For Securities:ABT

Summary

Abbott Laboratories' 2012 10-K filing reveals a company in the midst of a significant strategic shift with the announced separation of its research-based pharmaceuticals business into a new entity, AbbVie Inc. This separation, completed in early 2013, reshaped Abbott's business segments, with the Proprietary Pharmaceutical Products segment no longer existing post-separation. The company's diversified portfolio spans pharmaceuticals (prior to separation), diagnostics, nutritionals, and vascular products, each facing distinct competitive landscapes and market dynamics. Financially, Abbott demonstrated resilience, with notable revenue growth driven by its Pharmaceutical and Nutritional segments, supported by strong product performance like HUMIRA and new product introductions. The company also focused on operational efficiencies and margin improvement across its businesses, particularly in Diagnostics and Nutritionals. However, the report also highlights significant litigation charges, including a substantial settlement related to Depakote sales and marketing practices. The company's financial position remained robust, supported by strong operating cash flows, though debt levels were managed, including early extinguishment of a significant portion of long-term debt in preparation for the AbbVie separation.

Financial Highlights

55 data points
Beta

Revenue

$19.05B

53.3% Gross Margin

Net Income

$5.92B

31.1% Net Margin

EPS (Diluted)

$3.72

Total Assets

$67.23B

Cash & Equivalents

$10.80B

Free Cash Flow

$7.52B

Financial Statements
Beta
Revenue$19.05B
Cost of Revenue$8.90B
Gross Profit$10.15B
SG&A Expenses$6.74B
Operating Expenses$17.69B
Operating Income$1.36B
Interest Expense$320.00M
Net Income$5.92B
EPS (Basic)$3.76
EPS (Diluted)$3.72
Shares Outstanding (Basic)1.57B
Shares Outstanding (Diluted)1.59B

Key Highlights

  • 1Abbott Laboratories completed the separation of its research-based pharmaceuticals business into AbbVie Inc. on January 1, 2013, significantly altering its business structure.
  • 2The company reported strong performance in its Nutritional and Diagnostic Products segments, with strategic focus on margin improvement and new product development.
  • 3HUMIRA continued to be a key revenue driver, showing substantial sales growth across multiple indications.
  • 4Abbott faced and resolved significant litigation, including a $1.6 billion settlement related to Depakote sales and marketing practices.
  • 5The company invested heavily in research and development, with $4.3 billion allocated in 2012, focusing on pharmaceutical, medical, and nutritional products.
  • 6Abbott's financial health remained strong, with substantial operating cash flows and a manageable debt profile, further strengthened by debt extinguishment activities.
  • 7The company's Vascular Products segment saw revenue decrease, partly due to the winding down of certain third-party product agreements, but maintained market leadership with its Xience drug-eluting stent franchise.

Frequently Asked Questions

The most significant event was the planned separation of its research-based pharmaceuticals business into a new, independent public company named AbbVie Inc. This separation was completed on January 1, 2013, which materially changed Abbott's business structure and reporting segments.

Abbott demonstrated solid financial performance, with overall net sales increasing. Key growth drivers included HUMIRA and its Nutritional Products segment, while the company also focused on improving operating margins in its Diagnostics and Nutritional businesses. Despite significant litigation expenses, the company maintained strong operating cash flows.

Following the separation, Abbott Laboratories will primarily focus on its diversified medical products businesses, including Diagnostics, Nutritionals, Medical Devices (Vascular and other), and Established Pharmaceuticals (international branded generics). The Proprietary Pharmaceutical Products segment, which was largely the basis for AbbVie, will no longer be part of Abbott.

Yes, Abbott disclosed a significant charge of $1.6 billion in 2012 related to the settlement of federal, state, and consumer protection claims concerning the sales and marketing of its Depakote product. The company also discussed ongoing investigations into sales and marketing activities for its biliary and carotid/coronary stents.